Ligands of the translocator protein (TSPO) elicit pleiotropic neuroprotective effects that represent emerging treatment strategies for several neurodegenerative conditions. To investigate the potential of TSPO as a therapeutic target for Alzheimer's disease (AD), the current study assessed the effects of the TSPO ligand Ro5-4864 on the development of neuropathology in 3xTgAD mice. The effects of the TSPO ligand on neurosteroidogenesis and AD-related neuropathology, including ␤-amyloid accumulation, gliosis, and behavioral impairment, were examined under both early intervention (7-month-old young-adult male mice with low pathology) and treatment (24-month-old, aged male mice with advanced neuropathology) conditions. Ro5-4864 treatment not only effectively attenuated development of neuropathology and behavioral impairment in young-adult mice but also reversed these indices in aged 3xTgAD mice. Reduced levels of soluble ␤-amyloid were also observed by the combination of TSPO ligands Ro5-4864 and PK11195 in nontransgenic mice. These findings suggest that TSPO is a promising target for the development of pleiotropic treatment strategies for the management of AD.
Introduction
Ligands of translocator protein (TSPO), a mitochondrial molecule involved in the control of steroidogenesis (Papadopoulos et al., 2006b) , elicit pleiotropic neuroprotective effects, promoting nerve regeneration while reducing oxidative damage, apoptosis, and gliosis (Rupprecht et al., 2010) . Increased neurosteroid synthesis is perhaps the best characterized effect of TSPO ligands and most likely contributes at least in part to the plethora of established neuroprotective actions and anxiolytic and antidepressant behavioral effects (Rupprecht et al., 2010) . Consequently, TSPO ligands are under investigation for use in the treatment of a range of neurological disorders, including traumatic brain injury (Papadopoulos and Lecanu, 2009 ), peripheral neuropathies (Giatti et al., 2009) , inflammatory conditions (Veiga et al., 2005) , chronic pain (Torres et al., 2000) , depression (Gavioli et al., 2003) , and anxiety (Rupprecht et al., 2009) . Although potential therapeutic applications of TSPO ligands to Alzheimer's disease (AD) have been suggested (Veenman and Gavish, 2000; Papadopoulos et al., 2006a) , to date AD-related investigations of TSPO ligands have assessed only their utility in detecting gliosis via in vivo PET imaging in AD patients and mouse models of AD (Edison et al., 2008; Ji et al., 2008; Yasuno et al., 2008) .
Although the mechanisms of AD pathogenesis remain to be fully resolved, the leading hypothesis posits that the disease is initiated and driven by prolonged elevation in levels of ␤-amyloid protein (A␤) (Walsh and Selkoe, 2007) . Despite enormous effort to develop therapies that specifically reduce A␤ accumulation, thus far these strategies have proven unsuccessful clinically. TSPO ligands may offer an alternative to specific A␤-regulating strategies in that they simultaneously target multiple facets of the neurodegenerative cascade, perhaps including not only A␤ accumulation but also aspects of neuroinflammation, oxidative stress, mitochondrial dysfunction, and neuronal loss (Rupprecht et al., 2010) .
To investigate the potential of TSPO as a therapeutic target for AD, the current study assessed the effects of TSPO ligand Ro5-4864 in the 3xTgAD mouse model of AD (Oddo et al., 2003) . The effects of Ro5-4864 on neurosteroidogenesis and AD-related neuropathology, including A␤ accumulation, gliosis, and behavioral impairment, were assessed in both young-adult 3xTgAD mice with mild pathology and aged 3xTgAD mice with advanced neuropathology, allowing insight into protective actions under early versus late intervention scenarios. Because TSPO ligands can differentially modulate TSPO activities, we also compared the independent and combined effects of Ro5-4864 with PK-11195, a nonbenzodiazepine TSPO ligand, on regulation of A␤ levels in nontransgenic (non-Tg) mice.
Materials and Methods
Animals and treatments. Male homozygous 3xTgAD and non-Tg C57BL/6 mice (The Jackson Laboratory) were maintained at the Univer-sity of Southern California vivarium facilities with food and water available ad libitum. In experiments with young-adult mice, males (age 4 months) were gonadectomized (GDX) to deplete gonadal sources of sex hormones and preclude TSPO-ligand upregulation of steroidogenesis in the testes. In studies with young-adult 3xTgAD mice, GDX and sham-GDX mice were divided into three groups (N ϭ 7-10/group): sham ϩ vehicle, GDX ϩ vehicle, and GDX ϩ Ro5-4864; and administered Ro5-4864 (3 mg/kg) or vehicle (1% DMSO in canola oil) by injection (i.p.) once weekly for 3 months. This dose of Ro5-4864 has been widely used to yield neuroprotective effects in vivo (Veiga et al., 2005; Giatti et al., 2009) . In experiments with aged 3xTgAD mice, males (age 23 months, N ϭ 6/group) were similarly injected with Ro5-4864 or vehicle for 4 weeks. In studies with non-Tg C57BL/6 mice, males were GDX or sham-GDX at age 3 months and then assigned to one of the following groups (N ϭ 6 or 7/group): sham ϩ vehicle, GDX ϩ vehicle, GDX ϩ Ro5-4864, GDX ϩ PK-11195, or GDX ϩ PK-11195 ϩ Ro5-4864. Treatments of either vehicle, Ro5-4864 (3 mg/kg) or PK-11195 (3 mg/kg), were administered via once weekly injection (i.p.) beginning 2 weeks after surgery and continuing for 4 weeks. Mice were anesthetized (80 mg/kg ketamine/5 mg/kg xylazine; i.p.) and perfused with ice-cold saline 48 h after the final injection. Brains were bisected, with one hemisphere immersion fixed in 4% paraformaldehyde/0.1 M PBS for 48 h and the limbic regions of the other hemisphere frozen on dry ice for neurosteroid assessment. All experiments were approved by the University of Southern California Institutional Animal Care and Use Committee.
Immunohistochemistry. Fixed hemibrains were sectioned exhaustively in the horizontal plane at 40 m. Some sections were labeled using antibodies directed against A␤ (#71-58000, 1:300 dilution; Zymed) or hyperphosphorylated tau (AT8, 1:1000 dilution; Pierce Chemical) using a standard avidin: biotinylated enzyme complex immunoperoxidase method as previously described (Rosario, 2006) . A␤-immunoreactive load was calculated as percentage of total pixel area positively labeled in binary images created by thresholding digitally captured grayscale images of high-magnification fields (420 ϫ 330 m) as previously described (Cummings et al., 2002) . Mean load values were averaged from two or three nonoverlapping fields from each brain region in five sections per animal. AT8 immunoreactivity was quantified by counting cells strongly immunoreactive over the entire cell surface, as previously described .
Other sections were labeled using antibodies directed against ionized calcium binding adaptor molecule-1 (IBA-1, Wako Chemicals) as a marker of microglial activation (Ito et al., 1998) or GFAP (clone GA5; Sigma-Aldrich) as a marker of astrocyte reactivity (Middeldorp and Hol, 2011), as previously described (Barreto et al., 2009) . IBA-1 and GFAP immunoreactivities were quantified by volume density morphometric analysis (Weibel, 1979) . Experimenters were blinded to treatment conditions during quantification.
Behavioral testing procedures. Anxiety and exploratory activity were assessed in the elevated plus maze (EPM), and spontaneous alternation behavior (SAB) was assessed in the Y-maze, as previously described . Mice were tested in the EPM 24 h after the fourth injection. The total number of arm entries was scored as a marker of exploratory activity, and duration spent exploring the open arm was scored as an index of anxiety-related behavior. After a 1 h interval, SAB was assessed. Arm choices were recorded, and the SAB score was calculated as the number of alternations divided by the total number of alternation opportunities. One outlier was excluded from analysis from the 7-month-old sham ϩ vehicle group.
Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of neuroactive steroids.
Samples were homogenized and purified by organic phase extraction for LC-MS/MS analysis as previously described (Caruso et al., 2008) . The LC-MS/MS system consisted of a linear ion trap-mass spectrometer (LTQ, ThermoElectron) equipped with a Surveyor liquid chromatography (LC) Pump Plus and a Surveyor Autosampler Plus (ThermoElectron). Chromatographic separation was performed on a Inertsil ODS-2 RP-C18 column (5 m, 150 mm ϫ 4.6 mm i.d.; GL Sciences), and the MS was operated with atmospheric pressure chemical ionization in the positive ion mode. LC-MS/MS peaks were evaluated using Excalibur release 2.0 SR2 (ThermoFisher). Calibration curves were prepared and analyzed using deuterated internal standards. Limits of quantification, precision, and accuracy have been previously reported (Caruso et al., 2008) . One outlier was excluded from analysis of progesterone levels from the GDX ϩ vehicle group.
A␤ ELISA. Homogenates of hemibrains from non-Tg mice were prepared as previously described (Ramsden et al., 2003) and used to quantify levels of soluble A␤x-40 and A␤x-42 using commercially available ELISA kits according to the manufacturer's instructions (Wako).
Data analysis. Data were analyzed using the Statistical Package for Social Sciences (SPSS, version 11.5). The effect of GDX and Ro5-4864 administration in the young-adult 3xTgAD mice was assessed by oneway ANOVA followed by least-square difference tests. The effect of Ro5-4864 treatment in the aged-senescent 3xTgAD mice was determined by t tests. The effect of treatment on A␤ levels in C57BL/6 mice was assessed by linear mixed model followed by least-square difference tests. Significance was set at a threshold of p Ͻ 0.05. Data are mean Ϯ SEM.
Results

Ro5-4864 attenuates hippocampal A␤ accumulation in 3xTgAD mice
In young-adult 3xTgAD mice, a significant effect of treatment was observed on A␤-immunoreactive load in the hippocampal CA1 region (F ϭ 4.53, p ϭ 0.02). GDX accelerated A␤ accumulation in hippocampus CA1, increasing A␤-immunoreactive load of vehicle-treated GDX mice compared with sham mice (Fig.  1 A, B,K ). Ro5-4864 treatment attenuated A␤ accumulation in the CA1 region of GDX mice, with A␤ load almost halved in Ro5-4864 compared with vehicle-treated GDX mice ( Fig.  1 B, C,K ) . A␤ load in the subiculum was not significantly affected by either GDX (Fig. 1 F, G,L) or Ro5-4864 administration (Fig.  1G , H, L; F ϭ 2.86, p ϭ 0.08). In aged 3xTgAD mice, Ro5-4864 treatment also decreased A␤ load in the hippocampus CA1 by Ͼ50% (t ϭ 2.08, p ϭ 0.03; Fig. 1 D, E,K ) . A trend toward decreased subiculum A␤ load was noted in aged mice administered Ro5-4864; however, this did not reach significance (t ϭ 1.70, p ϭ 0.06; Fig. 1 I, J,L) .
As an indicator of tau neuropathology, the number of cells immunoreactive with the phospho-specific tau antibody, AT8, was assessed in aged 3xTgAD mice. No significant difference in the number of AT8-immunoreactive neurons between vehicle (58.3 Ϯ 15.3) and 3) treated groups was observed (t ϭ 0.76, p ϭ 0.23).
Ro5-4864 decreases gliosis in 3xTgAD mice
In young-adult 3xTgAD mice, significant effects of treatment were observed on both GFAP (F ϭ 29.88, p Ͻ 0.001) and IBA-1 (F ϭ 39.60, p Ͻ 0.001) hippocampal immunoreactivities. GDX was associated with modest but significant increases in hippocampal GFAP (Fig. 2 A, B ,K ) and IBA-1 immunoreactivities (Fig. 2 F, G,L) . Ro5-4864 administration in GDX mice more than halved GFAP (Fig. 1 B, C,K ) and IBA-1 (Fig. 2G, H, L) immunoreactivities. Similarly, Ro5-4864 treatment strongly lowered GFAP (t ϭ 6.76, p Ͻ 0.001; Fig. 2 D, E,K ) and IBA-1 (t ϭ 6.00, p Ͻ 0.001; Fig. 2 I, J,L) immunoreactivities in the aged 3xTgAD mice.
Ro5-4864 alters brain testosterone and progesterone levels in 3xTgAD mice
Because TSPO regulates synthesis of neuroactive steroids, we measured brain levels of several steroids. In young-adult 3xTgAD mice, a significant effect of treatment was observed on testosterone (F ϭ 5.43 p ϭ 0.02) and progesterone (F ϭ 6.25, p ϭ 0.008) levels. GDX depleted brain levels of testosterone (Fig. 3A) and progesterone (Fig. 3B) , whereas Ro5-4864 administration in GDX mice increased brain testosterone and progesterone com-pared with vehicle-treated GDX mice (Fig. 3 A, B ). Brain levels of pregnenolone ( p ϭ 0.54), iso-pregnanolone ( p ϭ 0.25), dihydroprogesterone ( p ϭ 0.17), tetrahydroprogesterone ( p ϭ 0.60), 17␤-estradiol ( p ϭ 0.15), and dihydrotestosterone ( p ϭ 0.97) were not significantly affected by Ro5-4864 treatment in GDX mice (data not shown).
Ro5-4864 administration did not significantly alter brain levels of testosterone (t ϭ Ϫ1.51, p ϭ 0.19; Fig. 3A ) in aged 3xTgAD mice; however, brain levels of progesterone (t ϭ 4.15, p Ͻ 0.01; Fig. 3B ) and its metabolites were decreased: dihydroprogesterone (vehicle ϭ 39.8 Ϯ 3.44; Ro5-4864 ϭ 20.0 Ϯ 3.51; t ϭ 3.96, p Ͻ 0.01), and tetrahydroprogesterone (vehicle ϭ 1.7 Ϯ 0.50; Ro5-4864 ϭ 0.2 Ϯ 0.09; t ϭ 2.54, p Ͻ 0.05). Brain pregnenolone (p ϭ 0.27), iso-pregnanolone (p ϭ 0.18), E2 (p ϭ 0.14), and dihydrotestosterone (p ϭ 0.34) levels were not significantly changed after Ro5-4864 treatment in the aged mice (data not shown).
Ro5-4864 improves behavioral measures in 3xTgAD mice
In young-adult 3xTgAD mice, anxiety-related behavior in the EPM was significantly affected by treatment (F ϭ 6.86, p ϭ 0.006). GDX increased anxiety-related behavior, with GDX mice spending significantly less time exploring the open arms of the EPM compared with sham-GDX mice (Fig. 3C) . A trend toward decreased anxiety-related behavior was observed in Ro5-4864-treated mice, with a nonsignificant increase in duration spent exploring the open arm compared with vehicle-treated GDX mice ( p ϭ 0.054). In the aged 3xTgAD mice, Ro5-4864 treatment was associated with decreased anxiety, with Ro5-4864-treated mice spending more time exploring the open arms of the EPM (t ϭ 2.13, p ϭ 0.03). No significant effect of treatment was observed on the number of arm entries in either the young-adult or aged mice, suggesting no effect of treatment on exploratory activity.
SAB in the Y-maze, a hippocampal-dependent measure of working memory and attention (Lalonde, 2002) , was also significantly affected by treatment in the young-adult mice (F ϭ 8.69, p ϭ 0.002). The GDX group exhibited significantly impaired SAB compared with sham GDX mice (Fig. 3D) . Significantly improved SAB performance was observed in GDX mice treated with Ro5-4864 compared with vehicle-treated GDX mice. Ro5-4864 treatment also significantly improved SAB performance in aged 3xTgAD mice compared with vehicle-treated controls (t ϭ 2.08, p ϭ 0.03).
Combined Ro5-4864 and PK-11195 treatment reduces A␤ in non-Tg mice
There are several known TSPO ligands that differentially activate TSPO. To begin investigating how other TSPO ligands affect ADrelated pathologies, we compared Ro5-4864 with PK-11195, a nonbenzodiazepine TSPO ligand, for A␤-lowering actions in non-Tg male mice. A␤-40 levels were significantly affected by TSPO ligand treatments in non-Tg mice (F ϭ 4.33, pϭ0.003; Fig.  4A ). Ro5-4864 reduced A␤-40 levels ϳ15% compared with GDX mice ( p Ͻ 0.02). Although mean A␤-40 levels were ϳ10% lower in PK-11195-treated compared with GDX mice, this was not significantly different compared with either vehicle or Ro5-4864-treated groups. Coadministration of Ro5-4864 and PK-11195 had an additive effect, decreasing A␤-40 levels by Ͼ25% compared with vehicle-treated GDX mice ( p Ͻ 0.001). A␤-40 levels in Ro5-4864 ϩ PK-11195-treated mice were significantly reduced compared with even sham-operated mice ( p Ͻ 0.02). A similar but nonsignificant trend was observed for TSPO ligand treatments on A␤-42 levels (F ϭ 2.33, p ϭ 0.061; Fig. 4B ).
Discussion
TSPO ligands have been found to be neuroprotective after a wide range of insults, including peripheral nerve injury (e.g., Giatti et al., 2009) , traumatic brain injury (for review, see Papadopoulos and Lecanu, 2009), excitotoxic lesion (e.g., Veiga et al., 2005) , and inflammatory insult (e.g., Torres et al., 2000) . Our findings suggest that TSPO may also be a promising target for the development of therapeutics for the treatment of AD. We observe that TSPO ligands not only reduce the development of AD-related neuropathology in young-adult non-Tg and 3xTgAD mice but also reverse pathology and improve cognition in aged 3xTgAD mice.
Increased neurosteroidogenesis is an established mechanism of action of TSPO ligands. Prior observations that neurosteroid levels are altered in both normal aging and AD in humans , and the progesterone metabolite allopregnanolone (Chen et al., 2011) attenuate A␤ accumulation and improve memory deficits in 3xTgAD mice. In the current study, Ro5-4864 increased both testosterone and progesterone in young-adult 3xTgAD mice. However, the absence of similar regulation of neurosteroids by Ro5-4864 in aged 3xTgAD mice suggests that either neurosteroid regulation is not essential to the A␤-lowering actions of TSPO ligands or that the primary protective mechanism(s) of TSPO ligands differs in young versus aged mice. Elevated levels of additional neurosteroids, including pregnenolone and DHT, have also been observed in response to Ro5-4864 in other rodent paradigms (Giatti et al., 2009 ). Although it is unclear why different patterns of neurosteroid regulation are observed across studies, the spectrum of neurosteroids induced by TSPO ligands and the magnitude of these effects likely depend upon a variety of experimental parameters, including brain region, duration of TSPO ligand treatment, and latency between treatment and tissue collection.
Another important mechanism contributing to neuroprotective actions of TSPO ligands is reduction of gliosis and its associated proinflammatory effects. We observed strong morphological evidence of decreased astrocytic and microglial activation in young and aged 3xTgAD mice with Ro5-4864. Although the marked reduction in gliosis may have been a downstream result of reduced A␤ accumulation, previous studies have demonstrated that TSPO ligands act directly on glia to reduce indices of activation and proliferation (Choi et al., 2002) . Chronic neuroinflammation is a significant degenerative factor in AD, and anti-inflammatory drugs have shown some therapeutic promise for AD (Szekely et al., 2004) . Although TSPO ligands are under development for in vivo imaging of reactive gliosis in AD, our findings suggest that TSPO ligands may represent not only a marker of neuroinflammation but also a potential antiinflammatory treatment strategy for AD.
The most important outcome of the Ro5-4864 treatment is arguably the marked improvements in functional outcomes, increased working memory performance, and reduced anxiety behaviors in the 3xTgAD mice. Few studies have addressed the effects of TSPO ligands on learning and memory in rodents, although some have reported impaired (Holmes and Drugan, 1991) and others improved (Da Cunha et al., 1991) performance in a passive avoidance task. In both male and female 3xTgAD mice, we have reliably observed a strong correlation between A␤ neuropathology and SAB impairment (Rosario, 2006; . Therefore, the improved working memory performance observed in the current study is likely related to reduced neuropathology. Consistent with our observations in the 3xT-gAD mice, TSPO ligands are potent anxiolytics in both rodents and humans (Rupprecht et al., 2009 ). Anxiety may indeed be an early indicator of AD in people with mild cognitive impairment (Perry and Hodges, 1999) . Thus, TSPO ligands may simultaneously target multiple clinical features of AD, including memory function and anxiety behaviors.
Many new-generation, safe TSPO ligands have been developed for in vivo imaging in humans (Chauveau et al., 2008) ; however, these ligands may also have a therapeutic potential for the treatment of AD. Because TSPO expression is upregulated in the most severely affected regions of the AD brain, TSPO ligands may selectively target regions most affected by the disease. Together, these findings indicate that TSPO may be a promising target for the development of pleiotropic treatment strategies for the management of AD.
